Akebia Therapeutics Inc. (NASDAQ:AKBA) previous close was $3.33 while the outstanding shares total 153.82M. The firm has a beta of 1.74. AKBA’s shares traded higher over the last trading session, gaining 0.90% on 06/04/21. The shares fell to a low of $3.31 before closing at $3.36. Intraday shares traded counted 2.14 million, which was 43.81% higher than its 30-day average trading volume of 3.80M. The stock’s Relative Strength Index (RSI) is 51.47, with weekly volatility at 6.03% and ATR at 0.19. The AKBA stock’s 52-week price range has touched low of $2.09 and a $13.71 high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investors have identified the Biotechnology company Akebia Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $533.20 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Akebia Therapeutics Inc. (AKBA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 365.02 million total, with 172.68 million as their total liabilities.
AKBA were able to record -70.81 million as free cash flow during the 08/11/2021 quarter of the year, this saw their quarterly net cash flow reduce by 23.67 million. In cash movements, the company had a total of -70.75 million as operating cash flow.
Potential earnings growth for Akebia Therapeutics Inc. (AKBA)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/11/2021 quarter of the year, Akebia Therapeutics Inc. recorded a total of 52.3 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -69.16% coming in sequential stages and their sales for the 08/11/2021 quarter reducing by -8.4%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 25.59 million trying to sell their products during the last quarter, with the result yielding a gross income of 26.71 million. This allows shareholders to hold on to 153.82M with the recently reported earning now reading -0.45 cents per share. This is a figure that compared to analyst’s prediction for their 08/11/2021 (-0.45 cents a share).
Having a look at the company’s valuation, the company is expected to record -0.63 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AKBA sounds very interesting.
Is the stock of AKBA attractive?
In related news, CEO and President, Butler John P. sold 49,990 shares of the company’s stock in a transaction that recorded on Mar 01. The sale was performed at an average price of 3.40, for a total value of 169,771. As the sale deal closes, the SVP, Chief Operating Officer, Dahan Michel now sold 14,547 shares of the company’s stock, valued at 49,403. Also, SVP, Chief Legal Officer, Hadas Nicole R. sold 14,285 shares of the company’s stock in a deal that was recorded on Mar 01. The shares were price at an average price of 3.40 per share, with a total market value of 48,513. Following this completion of acquisition, the CCO, Faulkingham Dell now holds 6,749 shares of the company’s stock, valued at 22,920. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.30%.
